TARX (Tarsier Pharma) Other Current Receivables: $0.01 Mil (As of Dec. 2025)


What is Tarsier Pharma Other Current Receivables?

Tarsier Pharma TARX Other Current Receivables is $0.01 Mil as of Dec. 2025.

Tarsier Pharma's Other Current Receivables for the quarter that ended in Dec. 2025 was $0.01 Mil.

Tarsier Pharma's quarterly Other Current Receivables increased from Dec. 2024 ($0.01 Mil) to Jun. 2025 ($0.03 Mil) but then stayed the same from Jun. 2025 ($0.03 Mil) to Dec. 2025 ($0.01 Mil).

Tarsier Pharma's annual Other Current Receivables increased from Dec. 2023 ($0.01 Mil) to Dec. 2024 ($0.01 Mil) and increased from Dec. 2024 ($0.01 Mil) to Dec. 2025 ($0.01 Mil).

Tarsier Pharma Other Current Receivables Related Terms

Tarsier Pharma Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Tarsier Pharma's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tarsier Pharma Other Current Receivables Chart

Tarsier Pharma Annual Data
Trend Dec23 Dec24 Dec25
Other Current Receivables
0.01 0.01 0.01

Tarsier Pharma Semi-Annual Data
Dec23 Jun24 Dec24 Jun25 Dec25
Other Current Receivables 0.01 0.00 0.01 0.03 0.01

Tarsier Pharma Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of $0.01 Mil mean?
Tarsier Pharma (TARX) has a Other Current Receivables of $0.01 Mil as of Dec. 2025. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Tarsier Pharma and its competitors.
Is Tarsier Pharma's Other Current Receivables too high?
Tarsier Pharma's current Other Current Receivables is $0.01 Mil.
How does Tarsier Pharma's Other Current Receivables compare to ?
Tarsier Pharma's Other Current Receivables of $0.01 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Biotechnology company?
A good Other Current Receivables depends on the Biotechnology industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Tarsier Pharma and its competitors. Tarsier Pharma's current Other Current Receivables is $0.01 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tarsier Pharma stock overvalued right now?
Tarsier Pharma (TARX) has a current Other Current Receivables of $0.01 Mil. The current Other Current Receivables is $0.01 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Tarsier Pharma (TARX), the current Other Current Receivables is $0.01 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Tarsier Pharma Business Description

Comparable Companies
Tarsier Pharma Ltd is a late clinical stage biopharmaceutical company, focused on the development and commercialization of novel pharmaceutical therapies to address unmet needs in ocular diseases with underlying inflammatory pathologies. Its dazdotuftide platform technology is a bio-inspired immunomodulator designed to treat blinding inflammatory ocular diseases, and is currently being developed as both eye drops and intravitreal injections. The company's Product Candidate Pipeline includes TRS01 and TRS02.